olivLaw · US equity research
CollPlant Biotechnologies Ltd. CLGN
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842 · Vertical: Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
CollPlant Biotechnologies is a regenerative and aesthetic medicine company that produces recombinant human collagen (rhCollagen) in genetically engineered plants, targeting dermal fillers, 3D-bioprinted breast implants and bioinks for 3D bioprinting. The company reported revenues of about $2.4 million in fiscal 2025, mostly from an AbbVie milestone payment, and a total comprehensive loss of $11.5 million, which makes future funding a central question.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, CollPlant Biotechnologies Ltd. (CLGN) stock was 4.23 USD (+2.92% on the day), with market capitalisation 54.2 m USD, beta 0.65, 52-week range 2.73–22.40 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 57.8
- strong (55–70)
- Bollinger (20, 2)
- 3.42 – 4.37
- in the upper half of the band · %B 0.85 · band width 24.4%
- SMA 50 / 200
- 3.76 / 5.00
- mixed trend
- MACD (12, 26, 9)
- 0.12 / 0.08
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +24.0% | −1.1% | +25.1 pp | — |
| 3 months | +36.5% | −0.5% | +36.9 pp | — |
| 6 months | +2.4% | +4.4% | −2.0 pp | — |
| Year to date | −69.8% | +12.3% | −82.1 pp | — |
| 1 year | −80.9% | +13.5% | −94.5 pp | +2.0% |
| 3 years | −92.5% | +76.4% | −168.9 pp | −0.2% |
| 5 years | −98.1% | +63.7% | −161.8 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.0 m | 2.3 m | 6.1 m | 15.6 m | 299.0 k | 11.0 m | 515.0 k | 2.4 m |
| Revenue YoY | +982.9% | −53.8% | +164.8% | +154.9% | −98.1% | +3,565.2% | −95.3% | +360.4% |
| Net income | -6.2 m | -11.2 m | -5.8 m | 237.0 k | -16.9 m | -7.0 m | -16.6 m | -11.5 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | −7,241.4% | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -2.23 | -0.84 | 0.02 | -1.53 | -0.62 | -1.45 | -0.94 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | −7,750.0% | unavailable | unavailable | unavailable |
| net % | -124.6% | -481.6% | -94.1% | 1.5% | -5,660.5% | -64.0% | -3,225.0% | -484.6% |
| Free cash flow | -2.0 m | -7.2 m | -4.9 m | 1.1 m | -15.0 m | -3.7 m | -14.6 m | -9.4 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 5.6 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 6.1 m USD
- Total assets
- 10.8 m USD
- Debt / equity
- unavailable
- Current ratio
- 2.53x
- ROE
- -117.6%
- ROA
- -77.9%
- FCF margin
- -398.4%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 6.1 m | 15.6 m | 299.0 k | 11.0 m | 515.0 k | 2.4 m | SEC (XBRL)· 26 Mar 2026verified |
| Cost of revenue | 3.0 m | 2.0 m | 400.0 k | 2.0 m | 1.6 m | 835.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Gross profit | 3.1 m | 13.6 m | -101.0 k | 9.0 m | -1.1 m | 1.5 m | SEC (XBRL)· 26 Mar 2026verified |
| Research & development | 4.1 m | 7.6 m | 10.3 m | 10.5 m | 10.5 m | 8.2 m | SEC (XBRL)· 26 Mar 2026verified |
| Operating income | -5.6 m | 65.0 k | -17.1 m | -7.5 m | -17.3 m | -11.5 m | SEC (XBRL)· 26 Mar 2026verified |
| Depreciation & amortisation | 660.0 k | 773.0 k | 1.1 m | 1.1 m | 1.0 m | 912.0 k | SEC (XBRL)· 26 Mar 2026verified |
| EBITDA | -4.9 m ≈ | 838.0 k ≈ | -16.0 m ≈ | -6.4 m ≈ | -16.2 m ≈ | -10.6 m ≈ | SEC (XBRL)· 26 Mar 2026derived |
| Income tax | — | — | — | 60.0 m | 46.0 m | — | SEC (XBRL)· 26 Mar 2025verified |
| Net income | -5.8 m | 237.0 k | -16.9 m | -7.0 m | -16.6 m | -11.5 m | SEC (XBRL)· 26 Mar 2026verified |
| Diluted EPS | -0.84 | 0.02 | -1.53 | -0.62 | -1.45 | -0.94 | SEC (XBRL)· 26 Mar 2026verified |
| Weighted average diluted shares | 6.9 m | 12.0 m | 11.0 m | 11.4 m | 11.5 m | 12.2 m | SEC (XBRL)· 26 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 3.3 m | 13.1 m | 29.7 m | 26.7 m | 11.9 m | 5.6 m | SEC (XBRL)· 26 Mar 2026verified |
| Receivables | 830.0 k | 270.0 k | 9.0 k | — | 150.0 k | 1.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Inventories | 1.3 m | 1.1 m | 1.4 m | 714.0 k | 440.0 k | 573.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Current assets | 5.7 m | 45.1 m | 31.7 m | 28.0 m | 13.2 m | 6.7 m | SEC (XBRL)· 26 Mar 2026verified |
| Property, plant & equipment, net | 2.1 m | 2.7 m | 3.0 m | 2.8 m | 2.3 m | 1.5 m | SEC (XBRL)· 26 Mar 2026verified |
| Intangibles (excl. goodwill) | 82.0 k | 243.0 k | 245.0 k | 188.0 k | 131.0 k | 73.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Total assets | 10.8 m | 51.2 m | 37.8 m | 34.1 m | 18.7 m | 10.8 m | SEC (XBRL)· 26 Mar 2026verified |
| Short-term debt | — | 219.0 k | 321.0 k | — | — | — | SEC (XBRL)· 29 Mar 2023verified |
| Long-term debt | 11.0 k | 30.0 k | — | — | — | — | SEC (XBRL)· 24 Mar 2022verified |
| Current liabilities | 3.4 m | 3.0 m | 3.1 m | 3.3 m | 3.0 m | 2.7 m | SEC (XBRL)· 26 Mar 2026verified |
| Total liabilities | 6.4 m | 6.1 m | 5.5 m | 5.8 m | 5.2 m | 4.7 m | SEC (XBRL)· 26 Mar 2026verified |
| Equity | 4.5 m † | 45.1 m † | 32.3 m † | 28.3 m † | 13.5 m † | 6.1 m † | SEC (XBRL)· 26 Mar 2026verified |
| Shares outstanding at year end | 7.0 m | 10.8 m | 11.2 m | 11.5 m | 11.5 m | 12.8 m | SEC (XBRL)· 26 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -4.5 m | 2.5 m | -13.7 m | -2.8 m | -14.1 m | -9.4 m | SEC (XBRL)· 26 Mar 2026verified |
| Capex | 437.0 k | 1.4 m | 1.3 m | 954.0 k | 483.0 k | 28.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Free cash flow | -4.9 m ≈ | 1.1 m ≈ | -15.0 m ≈ | -3.7 m ≈ | -14.6 m ≈ | -9.4 m ≈ | SEC (XBRL)· 26 Mar 2026derived |
| Investing cash flow | -519.0 k | -31.6 m | 28.9 m | -1.2 m | -539.0 k | -27.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Financing cash flow | 4.5 m | 38.8 m | 1.9 m | 1.1 m | 9.0 k | 3.1 m | SEC (XBRL)· 26 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 27.1% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 54.2 m USD
Key indicators
Coverage and freshness
Score by group
27% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -484.6% | 14 (vs peers) | 23% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 99.4% | 100 (on a fixed band) | 31% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 2.5x | 100 (on a fixed band) | 15% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -17.4% | 0 (on a fixed band) | 31% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality· partial14/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
CollPlant Biotechnologies Ltd (CLGN). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 2.4 m USD in 2025; YoY growth 360.4%; net margin -484.6%; ROE -117.6%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 99.4%
- Current ratio: 2.5x
What contradicts it
- Net margin: -484.6%
- FCF yield: -17.4%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842) · same industry (4-digit SIC) · compared with 23 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ISRGIntuitive Surgical, Inc. | 167.1 bn | 58.3 | 18.0% | 25.5% | +20.5% | −16% / +55% |
| EWEdwards Lifesciences Corporation | 57.1 bn | 56.2 | 9.7% | 15.3% | +11.5% | +15% / +47% |
| SNNSmith & Nephew plc | 28.5 bn | 45.3 | 11.8% | 10.1% | +6.1% | −2% / +25% |
| STESTERIS plc | 24.2 bn | 30.0 | 11.4% | 13.3% | +8.7% | −7% / +23% |
| ZBHZimmer Biomet Holdings, Inc. | 20.8 bn | 27.9 | 6.0% | 9.0% | +7.2% | +13% / −5% |
| ALGNAlign Technology, Inc. | 11.6 bn | 24.0 | 11.9% | 11.8% | +0.9% | +12% / −23% |
| MSAMsa Safety Inc | 6.8 bn | 22.8 | 22.1% | 15.0% | +3.7% | +10% / +2% |
| ESTAEstablishment Labs Holdings Inc. | 2.0 bn | — | -175.3% | -15.8% | +27.1% | −3% / +161% |
| ENOVEnovis Corp | 1.4 bn | — | -54.3% | -48.0% | +6.7% | −19% / −51% |
| CDRECadre Holdings, Inc. | 1.3 bn | 33.8 | 11.6% | 5.6% | +7.5% | −28% / −4% |
| AVRAnteris Technologies Global Corp. | 596.4 m | — | -75.1% | -4,619.3% | −29.2% | +49% / unavailable |
| COCHEnvoy Medical, Inc. | 549.6 m | — | — | -11,304.8% | +7.1% | +749% / +216% |
| ZJYLJin Medical International Ltd. | 483.7 m | 309.0 | 4.1% | 5.8% | −12.0% | −39% / −87% |
| SMTISanara Medtech Inc. | 297.0 m | — | -147.7% | -29.2% | +19.0% | +55% / −0% |
| INGNInogen, Inc. | 191.6 m | — | -13.1% | -6.9% | +3.9% | +2% / +24% |
| LAKELakeland Industries, Inc. | 88.7 m | — | -19.6% | -14.0% | +15.2% | −41% / −39% |
| NTRBNutriband Inc. | 73.9 m | — | -100.7% | -430.4% | −4.8% | +23% / +140% |
| APTAlpha Pro Tech, Ltd. | 58.6 m | 14.1 | 6.6% | 6.8% | +2.3% | +25% / +17% |
| CLGNCollPlant Biotechnologies Ltd | 54.2 m | — | -117.6% | -484.6% | +360.4% | −81% / −92% |
| MYOMyomo, Inc. | 51.5 m | — | -123.8% | -33.5% | +25.7% | +46% / −58% |
| MLSSMilestone Scientific Inc. | 29.2 m | — | -121.7% | -44.0% | +4.0% | +6% / −61% |
| LFWDLifeward Ltd. | 17.2 m | — | -225.6% | -141.3% | −14.1% | −13% / −90% |
| CUPRCuprina Holdings (Cayman) Limited | 14.1 m | — | -1,115.0% | -9,366.7% | +9.2% | −64% / unavailable |
| BBLGBone Biologics Corporation | 1.2 m | — | -47.5% | — | 0.0% | −77% / −98% |
1- and 3-year price returns: for CLGN from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 26 Mar 2026; since then the company filed 6-K (04 Nov 2026), 6-K (03 Nov 2026), 6-K (02 Nov 2026), 6-K (29 Oct 2026), 6-K (15 Oct 2026), 6-K (09 Oct 2026).
In brief
CollPlant Biotechnologies is a regenerative and aesthetic medicine company that produces recombinant human collagen (rhCollagen) in genetically engineered plants, targeting dermal fillers, 3D-bioprinted breast implants and bioinks for 3D bioprinting. The company reported revenues of about $2.4 million in fiscal 2025, mostly from an AbbVie milestone payment, and a total comprehensive loss of $11.5 million, which makes future funding a central question.
SWOT
Strengths
- Plant-based recombinant collagen production is presented as the only commercially viable approach the company knows of, and the intellectual property is owned entirely within the group 1.
- Partnerships with AbbVie, STEMCELL and Stratasys provide external validation and development and commercialization channels without full cost borne by the company 1.
- Commercial products such as the Collink.3D bioinks already have a user base in research and development 1.
Weaknesses
- The company has recorded losses in nearly every year since its founding and carries a significant accumulated deficit 1.
- Revenue depends on occasional milestone payments rather than recurring sales, which makes financial results hard to predict 1.
- Experience producing rhCollagen at scale is limited, and the source warns that commercial expansion could prove difficult 1.
Opportunities
- If the AbbVie-partnered dermal filler advances, the company could receive further milestone payments, and rhCollagen could become a core ingredient for other manufacturers 1.
- A filler platform for patients with rapid weight loss could open a new segment if clinical studies confirm efficacy 1.
- Using bioprinted skin models for preclinical testing, as an alternative to animal testing, could widen product applications 1.
Threats
- The company could run short of adequate funding, and the source states that a lack of capital could force delays or termination of development programs 1.
- Development depends on partner decisions, and the source shows AbbVie determines next steps for the program on its own 1.
- Competitors with more advanced technologies or greater resources could reduce the company's market share 1.
Risks
- Going concern doubthigh
Management has concluded there is substantial doubt about the company's ability to continue as a going concern, and the auditor's report carries an explanatory paragraph to that effect 1.
- Need for new fundinghigh
Limited cash and uncertain partner payments could force equity or debt issuances, with dilution for shareholders 1.
- Dependence on a single partnermedium
The success of the dermal filler depends on AbbVie, which leads the studies and decides next steps, with no guarantee of further payments 1.
- Limited clinical datamedium
A lack of extensive clinical data could make physicians and payors reluctant toward the products, which could delay adoption 1.
- Dependence on tobacco plantslow
rhCollagen production relies on the availability of tobacco plants, and an interruption could delay production and affect commercial use 1.
Investment thesis
What would need to be true (bull case)
- If commercial partners advance the dermal filler into the clinic, the company could receive new milestone payments and stronger validation of its technology 1.
- The plant-based rhCollagen technology is presented as an ethical and scalable alternative, which could attract partners in regenerative medicine 1.
- The collagen tissue repair market is estimated to grow significantly, and niche products could benefit from that expansion 1.
What would break the thesis
- Recurring losses and the absence of stable revenue could force the company to dilute shareholders through new equity issues 1.
- Doubts about the going concern assumption could discourage investors and partners and make financing harder to obtain 1.
- Dependence on a large partner's decisions leaves the company with no control over the timing and success of its key products 1.
What to watch
- AbbVie decision on next steps for the dermal filler after reviewing interim results2026
- Final results of the dermal filler clinical study and any new milestone paymentnext 10-K
- New financing transactions or shareholder dilution, including method and terms2026
- Progress of the photocurable filler into clinical trials following non-clinical results2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 26 Mar 2026; since then the company filed 6-K (04 Nov 2026), 6-K (03 Nov 2026), 6-K (02 Nov 2026), 6-K (29 Oct 2026), 6-K (15 Oct 2026), 6-K (09 Oct 2026).
The business
CollPlant operates from Rehovot, Israel, and focuses on medical aesthetics and 3D bioprinting of tissues and organs. Its technology, based on plant genetic engineering, removes the need for animal-derived collagen, and the company says rhCollagen is structurally and functionally identical to the type I collagen produced by the human body 1. The shares moved to the Nasdaq Capital Market in September 2025 under the ticker CLGN 1.
Segments
Regenerative dermal fillers
The photocurable dermal filler is in advanced preclinical work, while a partnership with AbbVie covers a dermal filler already in the clinic. According to the source, AbbVie is reviewing interim results and next steps are to be determined by the partner 1.
3D-bioprinted breast implants
The 3D-bioprinted breast implants are in preclinical studies in large animals, with tissue integration and vascularization observed, but the source does not describe a confirmed clinical path 1. The global breast implant market is estimated at $3 billion, which describes the unmet need targeted 1.
Market context
The source estimates the human collagen tissue repair market, including bioinks and aesthetic medicine lines, at about $19.5 billion in 2025, projected to reach $44.2 billion in 2033 1. If this growth holds, niche products could find room, but the figures come from market research firms rather than company data.
Trends
- Demand for regenerative aestheticstailwind
Growing interest in aesthetic treatments based on tissue regeneration could support demand for recombinant collagen fillers, especially if commercial partners move products into the clinic 1.
- Patients treated with GLP-1 therapiestailwind
In February 2026 the company announced positioning its filler platform for facial volume loss linked to rapid weight reduction, including patients on GLP-1 therapies 1. This niche could generate new demand if clinical evidence supports it.
- Replacing animal-derived collagentailwind
Pressure for ethical and sustainable alternatives to animal collagen could favor plant-based products, if the market accepts the biocompatibility standards of rhCollagen 1.
- Financing conditions for small biotechsheadwind
Capital market conditions could become less favorable, and the source explicitly notes new funding might only be available on unfavorable terms or not at all, which could limit development 1.
Competitive position
The source notes that competition and rapid technological change could lead to competitors developing therapies or products more advanced or effective than the company's 1. On the collagen side, the alternatives are tissue-derived collagens, which the source considers less capable 1.
CollPlant's stated advantage is that its technology is the only commercially viable one known to it for mass production of rhCollagen type I, but the source acknowledges limited scale experience 1. A partner with broad commercial reach, such as AbbVie, can be both an advantage and a dependency.
- AbbVie (Allergan)ABBV
Development partner for the dermal filler, with rights to commercialize it in medical aesthetics 1.
- STEMCELL Technologies
Manufacturing and distribution partner that incorporates rhCollagen into cell culture kits 1.
- StratasysSSYS
Collaborator on industrial-scale bioprinting of implants using its P3 bioprinting technology 1.
- Tissue-derived collagen producers
Traditional suppliers of animal or human collagen, which the source ranks below rhCollagen in functionality 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)04 Nov 2026
- Current report (foreign issuer)03 Nov 2026
- Current report (foreign issuer)02 Nov 2026
- Current report (foreign issuer)29 Oct 2026
- Current report (foreign issuer)15 Oct 2026
- Current report (foreign issuer)09 Oct 2026
- Current report (foreign issuer)06 Oct 2026
- Current report (foreign issuer)30 Sept 2026
- Current report (foreign issuer)24 Sept 2026
- Current report (foreign issuer)22 Sept 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / CollPlant Biotechnologies Ltd. · 26 Mar 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.